10-Q: FOXO Technologies Reports Q3 2023 Results Amidst Restructuring and Financial Challenges

FOXO Technologies reported a net loss of $3.66 million for Q3 2023, as the company navigates financial difficulties and strategic shifts.

Summary

• FOXO Technologies reported a net loss of $3.66 million for the third quarter of 2023, a significant improvement compared to the $41.03 million loss in the same period of 2022.
• The company's total revenue decreased to $10,000 in Q3 2023 from $14,000 in Q3 2022, primarily due to reduced life insurance commissions.
• Operating expenses decreased to $3.45 million in Q3 2023 from $8.83 million in Q3 2022, driven by lower research and development costs and reduced selling, general, and administrative expenses.
• For the nine months ended September 30, 2023, the net loss was $22.59 million, compared to $76.93 million for the same period in 2022.
• The company's cash and cash equivalents stood at $42,000 as of September 30, 2023, down from $5.52 million at the end of 2022.
• FOXO has implemented cost-cutting measures, including layoffs, to reduce operating expenses.
• The company is focusing on its Bioinformatics Services and has paused sales of its Longevity Report for redevelopment.
• FOXO is facing a going concern uncertainty due to its history of losses and limited cash reserves.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including low cash reserves, a default on debt, and a history of losses. While there are some positive developments, such as cost-cutting measures and a strategic shift, the overall outlook is concerning.

Positives

• The company significantly reduced its net loss in Q3 2023 compared to the same period last year.
• Operating expenses have been substantially reduced through cost-cutting measures.
• FOXO has launched Bioinformatics Services, which is now a primary offering.
• The company completed a private placement in Q3 2023, raising approximately $477,000 net proceeds.
• The company has made progress in restructuring its debt through the PIK Note Amendment.

Negatives

• The company's revenue decreased significantly in Q3 2023 compared to the same period last year.
• FOXO's cash reserves are critically low, raising concerns about its ability to continue as a going concern.
• The company has paused sales of its Longevity Report, a key product offering.
• FOXO is in default on its Senior PIK Notes, which could lead to acceleration of the debt.
• The company has incurred significant impairment charges on intangible assets.

Risks

• FOXO faces substantial doubt about its ability to continue as a going concern due to its history of losses and limited cash reserves.
• The company's ability to raise additional capital is uncertain, and failure to do so could force it to curtail or suspend operations.
• The company is in default on its Senior PIK Notes, which could lead to acceleration of the debt and further financial strain.
• The company's reliance on third-party suppliers for its epigenetic testing services poses a risk to its operations.
• The company is subject to legal proceedings, including a settlement agreement with Smithline Family Trust II, which requires significant cash payments.
• The company's stock is subject to delisting from the NYSE American due to low share price and stockholders' deficit.
• The company's ability to commercialize its technology and achieve profitability is uncertain.

Future Outlook

The company expects to continue to incur operating losses in the near term to support the growth of its business and is actively pursuing additional funding through a combination of equity or debt financings. The company is also focusing on its Bioinformatics Services and redeveloping its Longevity Report.

Management Comments

• Management is focused on commercializing health and longevity science into products and services.
• Management believes that epigenetics has unique and impactful capabilities pertaining to health and longevity.
• Management is reviewing its strategic goals and anticipates a continued focus on epigenetics and longevity while expanding its focus outside of life insurance and more on health and wellness.

Industry Context

The company's focus on epigenetics and longevity aligns with growing interest in personalized medicine and preventative healthcare. However, the company faces competition in the personal health and wellness testing market and the life insurance industry. The company's shift towards Bioinformatics Services reflects a broader trend of leveraging data analysis in scientific research.

Comparison to Industry Standards

• The company's financial performance is significantly below industry standards for publicly traded companies, particularly in terms of revenue generation and profitability.
• The company's cash position is critically low compared to other companies in the biotechnology and health tech sectors.
• The company's reliance on debt financing and the default on its Senior PIK Notes is a significant concern compared to industry norms.
• The company's strategic shift towards Bioinformatics Services is a departure from its original focus on life insurance, which may be viewed as a sign of instability.
• The company's impairment charges on intangible assets are indicative of challenges in commercializing its technology.

Management Changes

Legal Proceedings

• The company entered into a settlement agreement with Smithline Family Trust II, agreeing to pay $2.3 million in cash.
• The company is also party to various other legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business.

Related Party Transactions

• The company obtained a $247 loan from Andrew J. Poole, a former director, to pay for directors and officers insurance.
• The company obtained a $43 loan from Andrew J. Poole, a former director, to pay for legal fees.
• The company has a Master Software and Services Agreement with KR8 AI Inc., where the Interim CEO and Interim CFO are equity owners.

Stakeholder Impact

• Shareholders face significant risk of loss due to the company's financial instability and potential delisting.
• Employees have been impacted by layoffs and departures.
• Customers may experience delays or changes in product offerings.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue ongoing capital raise initiatives.
• The company will continue discussions with the holders of the PIK Notes to cure the event of default.
• The company will focus on commercializing its Bioinformatics Services.
• The company will redevelop its Longevity Report.
• The company will seek to regain compliance with NYSE American listing standards.

Key Dates

Keywords

epigenetics, bioinformatics, biomarkers, life insurance, longevity, financial results, going concern, debt, capital raise, private placement